Drug profile · INN
vandetanib
ZACTIMA
vandetanib (ZACTIMA) is a ephrin receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
FDA: approved EMA: approved Antineoplastic and immunomodulating agents (L01) L01XE
US status approved
Patents linked 0
Pipeline programs 4
News articles 0
Drug details — vandetanib
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- ORAL
- Patents
- 0
- Programs
- 4
- Data quality
- 0.84
Quick answer
vandetanib (ZACTIMA) is a ephrin receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
Key facts
INN vandetanib
Brand ZACTIMA
Mechanism Ephrin receptor inhibitor
Target Ephrin receptor
Therapeutic class Antineoplastic and immunomodulating agents (L01)
Route ORAL
Formulation TABLET
ATC code L01XE
Mechanism of action
Ephrin receptor inhibitor
Primary target: Ephrin receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is vandetanib?
vandetanib (ZACTIMA) is a ephrin receptor inhibitor. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for vandetanib?
ZACTIMA is a marketed brand name for vandetanib. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of vandetanib?
vandetanib has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.